sale beat expect though ep slightli better oper margin
soft organ revenu growth guid line expect albeit
level still target hsd growth view revenue/ep target
reason slight upward bia remain enthus pki progress
appear larg captur current valuat
revenu grew y/i report basi ahead
consensu expect foreign exchang headwind expect note
diagnost organ growth exclud euroimmun period render
strength even impress initi nipt tulip contribut
blemish growth euroimmun gener growth vs
guidanc da growth expect
first good news ep grew y/i better expect
less good news would miss ep forecast spite stronger revenu
tax rate come point expect larg due
oper margin miss declin segment said import
note margin improv y/i may opportunist pull-
forward invest quarter revenu strength
revenu ep expect guid well consensu
respect translat organ growth compani easiest
comparison year y/i stack basi said includ
assum growth headwind associ export like icp-m
licens holdup relat shutdown approv usual complet day
hope would turn less impact guid given shutdown
end least first month quarter come back
recaptur occur confid abil meet beat full year target
like diminish without beat organ revenu growth would need grow
meet fy growth target absent upsid quarterli
organ growth comparison
organ revenu growth year seem reason us get
follow key growth assumpt tulip euroimmun vanadi
rememb much air time vanadi get expect
account sale neonat dx flat onesourc
y/i everyth els includ da seem like reason
assumpt potenti slight upward bia addit guidanc
margin expans well annual averag gener sinc
margin also grew period manag outlin
reason plan still unambiti target said ep guidanc seem
achiev get organ revenu growth
margin expans tax rate stabl share count cont page
pleas see page report import disclosur
past year increas invest made sever portfolio chang
divestitur acquisit launch number new product action
appear bear fruit believ risk/reward get interest confid
build outlook msd core revenu growth growth euroimmun
ep trend slightli ahead expect
revenu growth acceler
beyond
deploy strategi ep
balanc invest growth area
hsd
deploy strategi ep
ou growth demonstr potenti
revenu growth limit
margin improv come short
provid divers array product servic address
diagnost research environment industri laboratori servic market report
two busi segment discoveri analyt solut diagnost
midst multi-year portfolio optim effort start bear fruit
number slower growth cyclic divestitur complet
combin new product/servic initi area next gener sequenc
acquisit euroimmun vanadi grown pki diagnost segment
increas inher growth rate msd-hsd level tradit slower
growth da segment improv via enhanc focu food/environment
applic combin alreadi strong onesourc pharma servic busi
increasingli confid compani thought built grow revenu
 sustain point better option attach
vanadi possibility/likelihood addit believ thesi somewhat
captur current valuat view outlook attract enough recommend
watch close purchas opportun increas price target
share translat ep line peer increas reflect
strong appreci group ytd said note dcf analysi
current trade robust premium price-to-earnings basi
compani report thomson eikon cowen compani
cowen vs consensu mm except organ organ fx ei oper margin bridg fx unplan bridg compens fx organ tax revenu metric mm except analyt currenc growth growth currenc growth organ growth statement mm except per count expens forecast sg expens forecast oper margin consensu forecast appear acceler invest due top line strength tax rate forecast contribut ep ep expect guidanc revenu upsid translat ep upsid due weaker expect margin lower expect tax rate share count contribut ep streetaccount consensu da revenu organ round line consensu expect bit forecast solid close year difficult comparison growth driven balanc strength life scienc appli end market streetaccount consensu organ look organ growth diagnost exclud euroimmun grew robust y/i appear broad base strength though genet test tulip/ex-ei immunodiagnost note particularli strong importantli growth driver appear sustain streetaccount consensu organ revenu beat expect driven solid organ revenu growth beat expect euroimmun revenu bit lighter expect though attribut time order gross margin light cowen
compani report cowen compani
mm except yr organ fx headwind export licens account organ fx impact growth currenc organ exchang analyt core growthpurchas account growth note food businessconst currenc note onesourc businessorgan stack basi embed assumpt growth total bit may conserv given food driver cyclic foreign exchang multispectr divestitur headwind quarter organicpurchas account dx organ growth tradit organ growth currenc organ core growth exclud ei ei add core growth total ei grow y/i exchang cowen
compani report thomson eikon cowen compani
mm except yr cagrcommentsnet organ fx headwind export licens organ fx impact constant north op margin expans driven gross margin expect increas revenu gener sg expect increas revenu oper oper margin expans like non-oper interest interest/otherearn tax rate per share export headwind fx share share count consensu except gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
downsid risk includ limit macroeconom deterior
current level inabl execut integr eros market share price
due competit inabl deliv incremental/decrement margin target
value-destruct upsid risk includ limit better expect
revenue/ep disciplin buyer seller improv
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc januari et dissemin januari et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
